A non-aqueous electrolyte solution for a battery includes: an additive A which is a compound represented by formula (I); and an additive B which is at least one selected from the group consisting of an aromatic compound having at least one of a halogen atom or an alkyl group and a carbamate, and which is a compound other than carbonates or a cyclic sulfates. In formula (I), R.sup.1 represents a group represented by formula (II) or a group represented by formula (III) and R.sup.2 represents H, a C1-6 alkyl group, a group represented by formula (II), or a group represented by formula (III); or R.sup.1 and R.sup.2 represent groups which combine to form a benzene ring or cyclohexyl ring. In formula (II), R.sup.3 represents a halogen atom, a C1-6 alkyl group, a C1-6 alkyl halide group, a C1-6 alkoxy group, or a group represented by formula (IV). ##STR00001##

A non-aqueous electrolyte solution for a battery includes: an additive A which is a compound represented by formula (I); and an additive B which is at least one selected from the group consisting of an aromatic compound having at least one of a halogen atom or an alkyl group and a carbamate, and which is a compound other than carbonates or a cyclic sulfates. In formula (I), R.sup.1 represents a group represented by formula (II) or a group represented by formula (III) and R.sup.2 represents H, a C1-6 alkyl group, a group represented by formula (II), or a group represented by formula (III); or R.sup.1 and R.sup.2 represent groups which combine to form a benzene ring or cyclohexyl ring. In formula (II), R.sup.3 represents a halogen atom, a C1-6 alkyl group, a C1-6 alkyl halide group, a C1-6 alkoxy group, or a group represented by formula (IV). ##STR00001##

An electrolyte includes a compound of formula 1: ##STR00001## formula 1. R.sub.1 and R.sub.2 are each independently selected from H, halogen atom, a substituted or unsubstituted C.sub.1-10 alkyl group, a substituted or unsubstituted C.sub.3-10 cycloalkyl group, a substituted or unsubstituted C.sub.2-10 alkenyl group, a substituted or unsubstituted C.sub.2-10 alkynyl group, a substituted or unsubstituted C.sub.1-10 alkoxy group, a substituted or unsubstituted C.sub.6-10 aryl group, a substituted or unsubstituted C.sub.3-10 heteroaryl group, or any combination thereof. R is selected from a substituted or unsubstituted C.sub.1-10 alkyl group, a substituted or unsubstituted C.sub.3-10 cycloalkyl group, a substituted or unsubstituted C.sub.2-10 alkenyl group, a substituted or unsubstituted C.sub.2-10 alkynyl group, a substituted or unsubstituted C.sub.1-10 alkoxy group, a substituted or unsubstituted C.sub.6-10 aryl group or a substituted or unsubstituted C.sub.3-10 heteroaryl group, a substituted or unsubstituted C.sub.3-10 heterocycloalkyl group, a butyrolactam group, ##STR00002##
or any combination thereof.

An electrolyte includes a compound of formula 1: ##STR00001## formula 1. R.sub.1 and R.sub.2 are each independently selected from H, halogen atom, a substituted or unsubstituted C.sub.1-10 alkyl group, a substituted or unsubstituted C.sub.3-10 cycloalkyl group, a substituted or unsubstituted C.sub.2-10 alkenyl group, a substituted or unsubstituted C.sub.2-10 alkynyl group, a substituted or unsubstituted C.sub.1-10 alkoxy group, a substituted or unsubstituted C.sub.6-10 aryl group, a substituted or unsubstituted C.sub.3-10 heteroaryl group, or any combination thereof. R is selected from a substituted or unsubstituted C.sub.1-10 alkyl group, a substituted or unsubstituted C.sub.3-10 cycloalkyl group, a substituted or unsubstituted C.sub.2-10 alkenyl group, a substituted or unsubstituted C.sub.2-10 alkynyl group, a substituted or unsubstituted C.sub.1-10 alkoxy group, a substituted or unsubstituted C.sub.6-10 aryl group or a substituted or unsubstituted C.sub.3-10 heteroaryl group, a substituted or unsubstituted C.sub.3-10 heterocycloalkyl group, a butyrolactam group, ##STR00002##
or any combination thereof.

Disclosed are a battery electrolyte solution and a battery. The battery electrolyte solution includes an organic solvent, an additive, and an electrolyte salt, and the electrolyte solution is in contact with a negative electrode plate; the organic solvent includes an ethyl group solvent, the additive includes fluoroethylene carbonate, the electrolyte salt includes a lithium salt, and percentages of the ethyl group solvent, the fluoroethylene carbonate, and the lithium salt in a total mass of the electrolyte solution are configured as follows: 0.4N.sup.3A+B.sup.2+C.sup.25.2N.sup.3, where N denotes a peeling strength value of the negative electrode plate, A, B, and C respectively denote a percentage of the mass of the ethyl group solvent, the fluoroethylene carbonate and the lithium salt in the total mass of the electrolyte solution.

Disclosed are a battery electrolyte solution and a battery. The battery electrolyte solution includes an organic solvent, an additive, and an electrolyte salt, and the electrolyte solution is in contact with a negative electrode plate; the organic solvent includes an ethyl group solvent, the additive includes fluoroethylene carbonate, the electrolyte salt includes a lithium salt, and percentages of the ethyl group solvent, the fluoroethylene carbonate, and the lithium salt in a total mass of the electrolyte solution are configured as follows: 0.4N.sup.3A+B.sup.2+C.sup.25.2N.sup.3, where N denotes a peeling strength value of the negative electrode plate, A, B, and C respectively denote a percentage of the mass of the ethyl group solvent, the fluoroethylene carbonate and the lithium salt in the total mass of the electrolyte solution.

New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.

New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R(I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R(I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.